Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Oxford BioMedica PLC banner

Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 812 GBX -1.34%
Market Cap: £981.3m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

OXB Price Targets Summary
Oxford BioMedica PLC

Wall Street analysts forecast OXB stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OXB is 806.31 GBX with a low forecast of 455.51 GBX and a high forecast of 1 018.5 GBX.

OXB Lowest Forecast
Wall Street Target
455.51 GBX
-44% Downside
OXB Average Forecast
Wall Street Target
806.31 GBX
-1% Downside
OXB Highest Forecast
Wall Street Target
1 018.5 GBX
25% Upside
Lowest
Price Target
455.51 GBX
44% Downside
Average
Price Target
806.31 GBX
1% Downside
Highest
Price Target
1 018.5 GBX
25% Upside
Oxford BioMedica PLC Competitors:
Price Targets
S
STG
Strip Tinning Holdings PLC
127% Upside
A
ANY
ANY Biztonsagi Nyomda Nyrt
-10% Downside
F
FLB
Fluidigm Corp
42% Upside
S
STG
Strip Tinning Holdings PLC
127% Upside
A
ANY
ANY Biztonsagi Nyomda Nyrt
-10% Downside
F
FLB
Fluidigm Corp
42% Upside

Revenue
Forecast

24% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
24% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

For the last 13 years the compound annual growth rate for Oxford BioMedica PLC's revenue is 24%. The projected CAGR for the next 4 years is 26%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss

What are analyst estimates?

See Also

Summary
OXB intrinsic value, competitors valuation, and company profile.
DCF Valuation
OXB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OXB stock valuation using valuation multiples.
Wall Street Estimates
OXB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OXB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OXB's stock price target?
Price Target
806.31 GBX

According to Wall Street analysts, the average 1-year price target for OXB is 806.31 GBX with a low forecast of 455.51 GBX and a high forecast of 1 018.5 GBX.

What is Oxford BioMedica PLC's Revenue forecast?
Projected CAGR
26%

For the last 13 years the compound annual growth rate for Oxford BioMedica PLC's revenue is 24%. The projected CAGR for the next 4 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 318,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.